Misplaced Pages

Ruxolitinib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by The chemistds (talk | contribs) at 13:26, 19 November 2011 (added CSID, InChI & InChIKey). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 13:26, 19 November 2011 by The chemistds (talk | contribs) (added CSID, InChI & InChIKey)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Ruxolitinib
Clinical data
Other namesINCB018424, INC424
Routes of
administration		Oral, topical
ATC code
  • none
Legal status
Legal status
Pharmacokinetic data
Bioavailability>95%
Metabolism<50% (hydroxylation, glucuronidation)
Excretion74% urine, 22% faeces
Identifiers
IUPAC name
  • (3R)-3-cyclopentyl-3-pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H18N6
Molar mass306.37 g/mol g·mol
3D model (JSmol)
SMILES
  • C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI
  • InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
  • Key:HFNKQEVNSGCOJV-OAHLLOKOSA-N

Ruxolitinib is a drug being investigated for the treatment of myeloproliferative diseases, plaque psoriasis, and various types of cancer. It is a Janus kinase inhibitor with selectivity for subtypes 1 and 2 of this enzyme.

Results from Phase II clinical trials suggest that the drug can substantially improve symptoms and reduce spleen size in myelofibrosis patients, but it has not been shown to produce remission. As of February 2011, it is undergoing Phase III trials studying myelofibrosis and polycythemia vera.

In June 2011, it was announced that both phase III trials of ruxolitinib in the treatment of myelofibrosis (COMFORT-I and -II) met their primary endpoints of a significant increase in number of patients experiencing at least 35% reduction of spleen volume.

In November 2011, Ruxolitinib was approved by the U.S. Food and Drug Administration for the treatment of intermediate or high-risk myelofibrosis based on results of the COMFORT-I and COMFORT-II Trials.

References

  1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. PMID 20699411
  3. PMID 20506062
  4. PMID 21245760
  5. PMID 21079613
  6. Clinical trial number NCT00952289 for "COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial" at ClinicalTrials.gov
  7. Clinical trial number NCT01243944 for "Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: The RESPONSE Trial" at ClinicalTrials.gov
  8. ASCO Annual Meeting 2011: JAK Inhibitor Ruxolitinib Demonstrates Significant Clinical Benefit in Myelofibrosis


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: